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3Abstract
γ-aminobutyric acid (GABA) type B receptor (GABAB) is an allosteric complex made
of two subunits, GB1 and GB2. Both subunits are composed of an extracellular Venus flytrap
domain (VFT) and a heptahelical transmembrane domain (HD). GB1 binds GABA and GB2
plays a major role in G-protein activation as well as in the high agonist affinity state of GB1.
How agonist affinity in GB1 is regulated in the receptor remains unknown. Here, we
demonstrate that GB2 VFT is a major molecular determinant involved in this control. We
show that isolated versions of GB1 and GB2 VFTs, in the absence of the HD and C-terminal
tails, can form hetero-oligomers as shown by time-resolved FRET. GB2 VFT and its
association with GB1 VFT control agonist affinity in GB1 in two ways. First, it exerts a direct
action on GB1 VFT as GB2 VFT increases slightly agonist affinity on the isolated GB1 VFT.
Second and most importantly, GB2 VFT prevents inhibitory interaction between the two main
domains (VFT and HD) of the GB1 subunit. According to this model, we propose that the HD
of GB1 prevents the possible natural closure of the GB1 VFT. In contrast, GB2 VFT
facilitates this closure. Finally, such inhibitory contacts between HD and VFT in GB1 could
be similar to those important to maintain the inactive state of the receptor.
4INTRODUCTION
γ-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central
nervous system, activates GABAA ligand-gated Cl- channels, as well as the G-protein-coupled
receptor (GPCR) GABAB (1,2). This receptor is found in either pre- or post-synaptic elements
in various types of neurons. As such, GABAB receptors play important role in brain function
as illustrated by the antispastic activity of the GABAB selective agonist baclofen (Lioresal®),
and its involvement in various types of epilepsy, as well as in nociception and drug addiction
(2).
GABAB receptors belong to the class-III GPCRs, together with metabotropic
glutamate (mGlu), extracellular Ca2+-sensing, and some pheromone and taste receptors (3).
Each of these receptors is composed of an extracellular domain called Venus flytrap (VFT)
where agonists bind, and an heptahelical domain (HD) responsible for the recognition and
activation of heterotrimeric G-proteins. Whereas mGlu and Ca2+-sensing receptors exist as
homodimers, GABAB receptor is an heterodimer composed of two homologous subunits, GB1
and GB2 (4-7) (Fig. 1a).
So far, only the heterodimeric form of the GABAB receptor has been shown to activate
G-proteins efficiently. Although only GB1 binds GABA, several important roles of GB2 have
been identified. First, GB2 masks an intracellular retention signal of GB1, such that GB1
reaches the cell surface only when associated with GB2 (2,8-10). Second, the HD of GB2
5contains all the determinants required for G-protein coupling and plays a pivotal role in G-
protein activation by the heteromer (11-15). Third, GB2 increases agonist, but not antagonist
affinity on GB1 (4,11), even though it does not appear to bind any natural ligand (16).
The ligand binding site of GB1 has been extensively studied (17-22). Modeling and
site-directed mutagenesis studies indicate ligands bind in the cleft that separates both lobes of
the GB1 VFT, as observed for ligand binding in many similar protein modules (23) including
the mGlu1 VFT (24,25). Antagonists are expected to prevent the closure of the GB1 VFT
(19), as observed in mGlu receptors (25,26). Conversely, agonists interact with residues from
both lobes of GB1 VFT and they stabilize a closed form of this domain (16,19). Such a
domain closure of the GB1 VFT has recently been shown to be sufficient to activate this
heterodimeric receptor (27).
Mechanism of the allosteric control of agonist affinity in GB1 by GB2 is unknown. It
is likely that the GB2 subunit controls agonist affinity by further stabilizing the closed state of
the GB1 VFT (28). Understanding this mechanism should have implications in the current
model of GABAB receptor activation, as it may help to explain how GABA binding in the
GB1 VFT can activate the GB2 HD. In addition, it may open new routes for the development
of positive allosteric compounds known to stabilize the active conformation of the dimeric
HDs and VFTs and to increase agonist affinity (29-31).
Here, we demonstrate that direct interaction between GB1 and GB2 VFTs is
responsible for the increase in agonist affinity in two ways. First, it prevents the HD of GB1 to
6decrease agonist affinity, and second, the interaction between the two VFTs by itself further
increases agonist affinity in GB1 VFT.
7MATERIAL AND METHODS
Materials
γ-aminobutyric acid (GABA) was obtained from Sigma (Saint-Quentin Fallavier,
France). CGP64213 was gift from Drs. W. Froestl and K. Kaupmann (Novartis Pharma,
Basel, Switzerland). [125I]-CGP64213 was purchased from Anawa (Zurich, Switzerland).
Culture media, foetal bovine serum (FBS) and other solutions used for cell culture were from
Invitrogen (Cergy Pontoise, France).
Contruction of GB1 and GB2 mutants
The plasmids pRK5 encoding the wild-type GB1a, GB1ASA and GB2 subunits tagged
with the hemagglutinin (HA) or c-myc epitope at their N-terminal ends, under the control of a
cytomegalovirus promotor, were described previously (10,11). Truncated versions of GB1 and
GB2 (∆GB1 and ∆GB2) were generated by replacing codons for Ile621 of GB1 and Leu511
of GB2 by a stop codon using Quik-Change mutagenesis protocol (Stratagene, La Jolla, CA).
Glycosylphosphatidylinositol-anchored VFT module of GB1 (GB1GPI) was constructed by
subcloning of a synthetic gene fragment incoding for the GPI anchor signal peptide of the
mouse PrPc (32), after the entire coding sequence of GB1 VFT (MluI-PshAI fragment).
PshAI-XbaI fragment of pRK-GB1a-HA, encoding for HD and C-terminus domains of GB1,
was replaced by a synthetic gene fragment created by hybridization of two complementary
oligonucleotides 5’-TGG TCA GAA GAT CCA GCA GCA CCG TGC TTT TCT CCT CCC
8CTC CTG TCA TCC TCC TCA TCT CCT TCC TCA TCT TCC TGA TCG TGG GAT
AAT-3’ and 5’-CTA GAT TAT CCC ACG ATC AGG AAG ATG AGG AAG GAG ATG
AGG AGG ATG ACA GGA GGG GAG GAG AAA AGC ACG GTG CTG CTG GAT CTT
CTG ACCA-3’. It results in the addition of the amino acid sequence
RRSSSTVLFSSPPVILLISFLIFLIVG after residue Val579 of GB1. Post-translationally, GPI
anchor signal peptide is cleaved after the second serine residue (S) of the tripeptide SSS
(printed in underlined) and a GPI modification is added on that one (33).
Glycosylphosphatidylinositol-anchored VFT module of GB2 (GB2GPI) was generated by PCR
and subcloned into the plasmid pRK5-GB1GPI, in replacement of MluI-PshAI fragment
encoding for GB1 VFT. In GB2GPI, GPI anchor signal peptide is added after residue Gln473 of
GB2 following by Thr-Leu-Val sequence due to the PshAI site. A truncated version of
metabotropic mGlu5 receptor (∆mG5) in the first intracellular loop (after residue Arg614) was
generated by PCR from mGlu5 receptor expression vector previously described (34), and
subcloned into pRK5-GB1-HA or -c-myc, in replacement of MluI-XbaI fragment encoding for
the entire sequence of GB1. Mutation S246A was introduced in ∆GB1 by subcloning ApaI-
PshAI fragment of pRK5-GB1(S246A) (19) into pRK5-∆GB1.
Cell culture and transfection
HEK-293 and COS-7 cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS and transfected by electroporation as described elsewhere (35).
9Ten million cells were transfected with plasmid DNA containing GB1ASA (2 µg), GB2 (2 µg),
∆GB1 (4 µg), ∆GB2 (4 µg) , GB1GPI (4 µg), GB2GPI (4 µg), ∆mG5 (4 µg), ∆GB1(S246A) (4
µg) and V2 vasopressin receptor (165 ng) and completed to a total amount of 10 µg plasmid
DNA with pRK5 empty vector.
Western blotting
Twenty hours after transfection, HEK-293 cells were washed with PBS (Ca2+- and
Mg2+- free) and harvested. The membranes were prepared as previously described (26). For
each sample, 50 µg of total protein was subjected to SDS-PAGE by using 10 %
polyacrylamide gels, transferred to nitrocellulose membrane (Hybond-C; Amersham
Pharmacia), and probed with anti-HA mouse monoclonal antibody (clone 12CA5; Roche,
Basel, Switzerland) at 0.1 µg/mL. Proteins were visualized by chemiluminescence (West
Pico; Pierce, Rockford, IL).
Cell surface quantification by ELISA
Twenty hours after transfection with HA-tagged versions of the constructs, HEK-293
cells were washed twice with phosphate-buffered saline solution (PBS), fixed with 4%
paraformaldehyde in PBS and then blocked with PBS plus 5% FBS. After 30 minutes reaction
with primary antibody (monoclonal anti-HA clone 3F10; Roche, Basel, Switzerland) at 0.5
µg/mL) in the same buffer, the goat anti-rat antibody coupled to horseradish peroxidase
(Jackson Immunoresearch, West Grove, PA) was applied for 30 minutes at 1 µg/mL. After
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intense washes with PBS, secondary antibody was detected and quantified instantaneously by
chemiluminescence (Supersignal West Femto; Pierce, Rockford, IL) using a Wallac Victor2
luminescence counter (Molecular Devices, St Grégoire, France).
Ligand binding assay
Ligand binding assay on intact HEK-293 cells was performed as previously described
using 0.1 nM [125I]-CGP64213 (11). Displacement curves were performed with at least 7
different concentrations of the displacer, and the curves were fitted according to the equation:
"y=[(ymax-ymin)/(1+(x/IC50)nH)) +ymin" where the IC50 is the concentration of the compound that
inhibits 50% of bound radioligand and nH is the Hill coefficient. Ki values were calculated
according to the equation IC50=Ki(1+[RL]/Kd), where [RL] and Kd are the concentration and
dissociation constant of the radioligand. Kd was determined assuming Ki=Kd in the case of
CGP64213.
Time-resolved FRET measurements
Time-resolved FRET experiments were conducted as described by Maurel et al.1. After
transfection, COS-7 cells were dispatched into a black 96-wells assay plate (COSTAR) at 1.5
x 105 cells per well in 200 µl of Dulbecco’s modified Eagle’s medium supplemented with
10% FBS. Twenty hours later, cells were rinsed in 100 µl Tris-Krebs buffer (20 mM Tris-Cl,
pH 7.4, 118 mM NaCl, 5.6 mM glucose, 1.2 mM KH2PO4, 1.2 mM MgSO4, 4.7 mM KCl, 1.8
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mM CaCl2) supplemented with BSA 0.1%. Then, cells were incubated in 100 µl of the same
buffer containing 3 nM of anti-HA monoclonal antibodies (12CA5) labeled with a
fluorescence donor molecule (europium cryptate-PBP1) and 9 nM of anti-c-myc monoclonal
antibodies (9E10) labeled with a fluorescence acceptor molecule (Alexa Fluor® 647;
Molecular Probes) (these two antibodies were kind gifts by Cis Bio International, Marcoule,
France). As negative control, 1 µM of unlabeled anti-c-myc antibodies (9E10) was added to
the couple of labeled antibodies in order to displace the FRET signal, or COS-7 were
incubated with only fluorescence donor antibodies. After four hours incubation at 4°C, cells
were rinsed with Tris-Krebs buffer to remove unbound antibodies, and fluorescence emissions
were monitored both at 620 nm and at 665 nm with a RubyStar spectrofluorimeter equipped
with a nitrogen laser as excitation source (337 nm) (BMG LabTechnologies, Champigny-sur-
Marne, France). A 400-µsec reading was used after a 50-µsec delay to allow for decay of
short-lived endogeneous fluorescence signals. Fluorescence collected at 620 nm is the total
europium cryptate signal and fluorescence at 665 nm is the FRET signal, and the ratio
R=[(fluorescence 665 nm/ fluorescence 620 nm) x 104] was computed. FRET signal was
expressed by Delta F (∆F) calculated using the formula ∆F = (Rpos - Rneg)/(Rneg) where
Rpos is the ratio for the positive energy transfer measured in wells incubated with both donor
and acceptor antibodies, and Rneg is the ratio for the negative energy transfer control. Total
                                                                                                                                                         
1
 Maurel et al., manuscript in preparation
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fluorescence emitted at 682 nm by the Alexa Fluor® 647 conjugates after excitation at 640
nm was measured using an AnalystTM reader (Molecular Devices) equipped with the
appropriate filters set (XF47 from Omega Optical).
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RESULTS
GB2 increases agonist affinity, but not antagonist affinity on GB1
Although GB1 bind any known GABAB ligands, agonist affinities are about 100 times
lower than those measured on native receptors (36). This is partly due to GB2, since its co-
expression with GB1 results in a 10 fold increase in agonist affinity (4). This effect of GB2
does not result from the targeting of GB1 to the cell surface, and so to a mature glycosylation
state, since a GB1 mutant able to reach the cell surface alone (GB1ASA in which the ER
retention signal RSRR is mutated into ASAR) still displays a low agonist affinity at the cell
surface (Fig. 1b and Table 1). A direct association between GB1 and GB2 appears therefore
necessary to control agonist affinity in this receptor. Co-expression of GB1 with GB2/1, a
chimeric subunit composed of the VFT of GB2 and the HD of GB1, or the replacement of the
HD of GB1 by that of GB2 in the chimeric GB1/2 subunit, also resulted in an increased
GABA affinity (Fig. 1b and Table 1). These observations suggest that both the GB2 VFT and
the HD of GB1 control agonist affinity on GB1.
VFT module constructs for GB1 and GB2
In order to elucidate the mechanism leading both GB2 VFT and GB1 HD to
allosterically control agonist affinity on GB1, isolated GB1 and GB2 VFTs were prepared by
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removing the HD and C-terminal domains of each subunit. These constructs were generated to
examine the possible direct interaction between GB1 and GB2 VFTs and the consequence on
GABA affinity, regardless the other regions of the subunits. To express either GB1 or GB2
VFTs at the cell surface, two series of constructs were prepared. The first constructs called
∆GB1 and ∆GB2 were generated by introducing a stop codon at the end of the first
intracellular loop of GB1 and GB2, respectively. As such, the VFTs were anchored in the
plasma membrane by the first transmembrane helix (TM1) of these subunits (Fig. 2a). For the
second constructs called GB1GPI and GB2GPI, the entire HD and C-terminal tail were replaced
by the glycosylphosphatidylinositol (GPI) anchor sequence of the PrPc prion protein (see
Material and Methods and Fig. 2a). In all cases, these constructs contain an N-terminal
epitope, either c-myc or HA inserted after a signal peptide allowing their easy detection at the
cell surface. Previous studies demonstrated that such epitope affected neither the
pharmacology nor the function of these subunits (10,11).
All constructs are correctly expressed in HEK-293 cells, and display the expected
molecular weight as shown in Western blot experiments (Fig. 2b). All constructs except
GB2GPI were found at the cell surface but at a density two to ten times lower than that of
GB1ASA as revealed by an anti-HA ELISA performed on intact cells (Fig. 2c). Finally, ∆GB1
and GB1GPI bind a competitive and membrane non-permeant radio-labeled antagonist
[125I]CGP64213, and this binding can be displaced by GABA demonstrating these constructs
retained their ability to bind GABAB ligands (Fig. 2d and Table 1). All together, these results
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show that ∆GB1, ∆GB2 and GB1GPI are correctly expressed at the cell surface, and that ∆GB1
and GB1GPI are correctly folded.
To examine whether an interaction between GB1 and GB2 VFTs could be detected,
the above described truncated GB1 and GB2 subunits as well as the wild-type subunits were
co-expressed. GB2 and ∆GB2 increase expression of ∆GB1 and GB1GPI at the cell surface.
Binding experiments show that total amount of radioligand bound to ∆GB1 at the cell surface
is increased in the presence of ∆GB2 (Fig. 3a). A higher increase is observed when ∆GB1 is
co-expressed with the full-length GB2 (Fig. 3a). Similarly, the amount of [125I]CGP64213
bound to GB1GPI at the cellular surface is also increased when this construct is co-expressed
with either ∆GB2 and GB2 (Fig. 3a). Since neither GB2 nor ∆GB2 changes CGP64213
affinity on these GB1 constructs (Table 1), these data show that GB2 and ∆GB2 increase the
number of [125I]CGP64213 binding sites at the cell surface. We further confirm that GB2 and
∆GB2 increase the amount of truncated GB1 constructs at the cell surface using an ELISA on
intact cells. The amount of HA-∆GB1 at the cell surface is increased after co-expression with
c-myc-∆GB2 or c-myc-GB2 (Fig. 3b). Thus, GB2 VFT either stabilizes ∆GB1 and GB1GPI at
the cell surface, or facilitates their targeting to the plasma membrane.
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GB1 and GB2 VFT modules assemble into heterodimeric complexes in the absence of
heptahelical domain
To demonstrate more directly that GB1 and GB2 VFTs interact with each other, co-
immunoprecipitation experiments were performed. Unfortunately, no interaction between
GB1 and GB2 VFTs was detected (data not shown), possibly because such complexes are not
stable enough and did not resist to the sample preparation. Indeed, although the deletion of the
C-terminal coiled-coil domain of the GB1 and GB2 subunits does not prevent heterodimer
formation, as shown by the normal functioning of the receptor, it largely decreases the amount
of GB2 co-precipitated with GB1 (9). This shows that the coil-coiled domains in the C-
terminal tails of these subunits strongly stabilize the heterodimer.
We therefore conducted time-resolved fluorescence resonance energy transfer (TR-
FRET) experiments as previously described (37) ( and Maurel et al., submitted). In this assay,
a FRET signal is measured at the surface of intact COS-7 cells between a donor molecule
(europium cryptate-PBP) linked to an anti-HA monoclonal antibody, and an acceptor
molecule (Alexa Fluor® 647) linked to an anti-c-myc-monoclonal antibody (Fig. 4a, Insert).
In this assay, the HA-tagged version of ∆GB1 and GB1GPI and the c-myc tagged version of
∆GB2 and GB2 (or other control constructs) were used. As shown in Fig. 4a and 5a, a FRET
signal is measured at 665 nm (the emission wavelength of Alexa Fluor® 647) after excitation
of the europium cryptate-PBP at 337 nm in cells expressing either HA-∆GB1 or HA-GB1GPI
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together with c-myc-∆GB2. To better compare the association efficiency of the different
partners, FRET signal was normalized with regard to c-myc tagged construct expression (4c et
5c). This signal is significantly higher than that measured in mock transfected cells.
Moreover, such a FRET signal was not detected when ∆GB1 and GB1GPI were co-expressed
with the c-myc-tagged V2 vasopressin receptor, a class-I GPCR (Fig. 4a and 5a). As shown in
Fig. 4b and 5b, this did not result from the low expression at the cell surface of the c-myc
tagged partners. A significant FRET signal was however measured between  ∆GB1 and
 ∆mG5 (the VFT domain of metabotropic mGlu5 receptor anchored to in the plasma
membrane via the first TM) and to a lower extent between  ∆GB1 and V2-R (Fig. 4a).
However, such signals were not observed with GB1GPI (Fig. 5a) suggesting that TM1 of
 ∆GB1 is likely involved in a non-specific interaction with other TM containing proteins. This
may be because the TM used to anchor  ∆GB1 at the cell surface (TM1 of GB1) is usually
associated with other TMs in the GB1 HD.
During these experiments, we also noticed GB1 and GB2 VFT modules form
homomeric complexes, as previously reported for both full-length GB1 and GB2 subunits 1.
Indeed, a FRET signal could be measured in cells expressing HA-GB1GPI and c-myc-∆GB1.
This signal is similar to that obtained with HA-∆GB1 and c-myc-∆GB2 or HA-GB1GPI and c-
myc-∆GB2 (Fig. 4a and 5a), consistent with GB1 VFT being able to oligomerize. Similar
FRET signal between ∆GB1 expressed alone and GB1GPI co-expressed with ∆GB1 suggest
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TM1 of ∆GB1 is not responsible for its homomerisation. Moreover, we found that the GB2
VFT can also form homo-oligomers in similar FRET experiments (data not shown).
Association between VFT modules of GB1 and GB2 increases agonist affinity on GB1
We then examined the possible influence of the GB1-GB2 VFTs interaction on agonist
affinity. To that aim GABA affinity was measured by displacement of radioligand
[125I]CGP64213 on intact cells expressing the above described constructs alone or in
combination (Table 1). In contrast to agonist, we verified that antagonist CGP64213 displaced
with a similar potency the radioligand for every combination examined, indicating that none
of the constructs co-expressed with GB1 affect antagonist affinity (Table 1).
As shown in Fig. 6a, ∆GB2 increases by a factor 16 GABA affinity on GB1ASA (Ki
values were 16.0 ± 1.4 and 1.0 ± 0.2 µM for GB1ASA expressed alone or with ∆GB2
respectively). This effect is specific since no change in GABA affinity was observed when
GB1ASA was co-expressed with ∆mG5 or ∆GB1(S246A), a GB1 construct unable to bind
GABAB ligands (19). Association between GB1A S A and ∆GB2 or ∆GB1(S246A) was
confirmed by measuring FRET signal between the co-expressed constructs (Fig. 6a, Insert).
These results further confirm ∆GB2 associates with GB1ASA and show that this interaction
increases GABA affinity on GB1.
Of interest, and as previously reported (22), GABA affinity on the isolated VFT of
GB1 (either ∆GB1 or GB1GPI) is close to that measured when GB1 is co-expressed with GB2
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(Ki values 1.0 ± 0.2, 0.7 ± 0.1 and 3.2 ± 0.2 µM, respectively), and 10-20 times higher than
that on GB1ASA (Table 1 and Fig. 6). This indicates that the HD of GB1 exerts an inhibitory
action on agonist affinity. GABA affinity on these truncated GB1 constructs can still be
further increased, although to a lower extent, after co-expression with either GB2 or ∆GB2 (3
and 2.5 fold, respectively) (Fig. 6b). Indeed, Ki values for GABA on ∆GB1 decreases from
1.0 ± 0.2 µM to 0.3 ± 0.1 µM and 0.4 ± 0.2 in the presence of GB2 and ∆GB2, respectively.
This shows that most of the increased agonist affinity resulting from GB1-GB2 association is
due to GB2 VFT preventing the HD of GB1 to decrease agonist affinity, rather than a direct
effect of GB2 VFT on the GB1 VFT closure.
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DISCUSSION
In this study, we show how the association between the VFTs of GABAB receptor
subunits GB1 and GB2 can allostericaly influence agonist affinity. GB2 VFT controls GB1
affinity for GABA in two ways. First, it exerts a direct action on GB1 VFT as GB2 VFT
increases slightly agonist affinity on the isolated GB1 VFT. Second and most importantly,
GB2 VFT prevents inhibitory interaction between the two main domains (VFT and HD) of the
GB1 subunit.
Negative allostery within the GB1 subunit
Inhibitory contacts that maintain GB1 subunit alone in a low affinity state may have
several origins. One possibility is that the direct interaction between the HD and the VFT
domain within the GB1 subunit contrains the VFT in a low agonist affinity state.
Alternatively, GB1 can exist as homodimer and interactions between the GB1 VFTs in the
homodimer could stabilize a low agonist affinity state. We exclude this latter possibility since
the isolated VFT of GB1 (both ∆GB1 and GB1GPI) adopts a high agonist affinity state even
though it is able to homodimerize. Accordingly, a direct interaction between the HD and the
VFT domains of GB1 is likely responsible for the low agonist affinity state. Such an
interaction has already been proposed by others but has never been demonstrated (22,38).
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Such a negative effect of the HD on agonist affinity in the VFT has also been reported for
other class-III GPCRs, the mGlu4 and mGlu8 receptors, using a similar approach (39,40).
Negative allostery of GB1 is controlled by GB2 VFT, and such a process is probably
not a specificity of the expression of this subunit in heterologous cells. Indeed, only a high
agonist affinity GABAB receptor is found in the brain. Moreover, GB1 needs to be associated
with GB2 to reach the cell surface in the central nervous system, and neither GB1-GB1 nor
GB2-GB2 homodimers couple efficiently to G-proteins (4,6).
How is the agonist affinity controlled?
Both GB1 and GB2 VFTs are structurally related to the VFT of mGlu1 metabotropic
receptor and to bacterial periplasmic binding proteins, as suggested by modeling studies
(16,17,19,21). Such domains are well-known to adopt either an open conformation (VFTo)
stabilized by antagonists (25,26), or a closed conformation (VFTc) stabilized by agonists
(24,26,27). VFT can oscillate between VFTo and VFTc states with an equilibrium constant
K1= [VFTc]/[VFTo]. A bound ligand will affect K1 by a factor α>1 in the case of an agonist
that stabilizes VFTc, and α<1 in the case of an antagonist that stabilizes VFTo or prevents the
VFT to reach the VFTc state (28).
Accordingly, ligand affinity in a VFT (Kd) depends on both the affinity of the ligand
in VFTo (KL), K1 and α:
Kd = KL (1+K1)/(1+αK1)
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According to this model, an increase in K1 (the receptor has a better tendency to reach the
closed state in the absence of ligand) results in a large increase in agonist affinity (28).
Moreover, and as observed in the case of the GABAB receptor, changing K1 results in minor
changes in antagonist affinity (28). We therefore propose that in the absence of GB2, HD of
GB1 decreases K1 (favors the VFTo state), an effect that is prevented when GB2 VFT
associates with GB1 VFT. In addition, GB1-GB2 VFTs association may further increase K1
(favors the VFTc state) and thus agonist affinity.
Implications for receptor activation
GB2 VFT and its association with GB1 VFT appear to play a crucial role in GABAB
receptor activation. In the absence of GABA, GB2 VFT constrains the receptor in an inactive
state whereas in the presence of agonist, it facilitates receptor activation. Indeed, the presence
of both GB1 and GB2 VFTs in the dimeric receptor is necessary for agonist stimulation. A
dimeric receptor constituted by GB1-GB2 HDs but possessing two identical VFTs (either
GB1 or GB2) display a large constitutive activity that cannot be further stimulated by agonists
(11).
Inhibitory contacts between HD and VFT in GB1 that controls agonist affinity could
be similar to those important for GABAB receptor activation. This model is supported by
several pieces of data. First, the fact that GB2 VFT increases agonist but not antagonist
affinity suggests that GB2 VFT stabilizes the active state of GB1. Second, we showed GB2
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VFT acts by releasing inhibitory contacts between HD and VFT of GB1. Third, positive
allosteric compounds of GABAB that likely bind in the HD increase both affinity and efficacy
of agonists (29). Finally, similar inhibitory interactions between HD and VFT in GB2 subunit
could exist due to the allosteric nature of the GABAB receptor, and these contacts could also
play a role in receptor activation.
Conclusion
In conclusion, our experiments emphasize the functional importance of VFT
interaction within the GABAB heterodimeric receptor and potentially to other class-III
GPCRs. Our data show that the direct interaction between the VFTs is not only important for
agonist activation of the receptor, as already reported for both GABAB (11) and mGlu
receptors (41), but also for the control of agonist affinity. Indeed, a recent study show that
mutations in the mGlu1 VFT that possibly prevents direct VFTs interaction within the
receptor dimer largely decrease agonist affinity (41). Perspectives of this work is to identify
regions of VFT and HD responsible for inhibitory contacts both at the GB1-GB2 VFTs and
HD-VFT interfaces.
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GABA Ki
(µM)
CGP64213 Ki
(nM)
GB1 22.3 ± 1.9* 1.4 ± 0.2*
GB1/2 8.2 ± 0.9° 4.0 ± 1.2°
GB1 + GB2 3.3 ± 0.6° 2.9 ± 0.2°
GB1ASA 16.0 ± 1.4 2.5 ± 0.2
GB1ASA + GB2 3.2 ± 0.3 2.8 ± 0.3
GB1ASA + GB2/1ASA 1.2 ± 0.4° 3.6 ± 0.6°
GB1ASA + ∆GB2 1.0 ± 0.1 2.1 ± 0.6
GB1ASA + ∆mG5 14.2 ± 1.4 1.8 ± 0.3
GB1ASA + ∆GB1S246A 18.3 ± 0.2 2.0 ± 0.1
∆GB1 1.0 ± 0.2 2.1 ± 0.4
∆GB1 + GB2 0.3 ± 0.1 1.5 ± 0.3
∆GB1 + ∆GB2 0.4 ± 0.1 1.8 ± 0.2
GB1GPI 0.7 ± 0.1 2.5 ± 0.3
Table 1: Affinity values of GABA and CGP64213 for GB1 and ∆GB1 alone or in
combination with different constructs. Ki for GABA and CGP64213 were determined from
displacement of [125I]CGP64213 binding on intact cells expressing the indicated subunit
combinations, as described in Materials and Methods. * indicates that the binding experiments
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were performed on crude membranes (data from (19)). ° values taken from (11). Values are
means ± s.e.m. of at least three independent determinations.
Legends to Figures
Figure 1: VFT module of GB2 and HD of either GB1 and GB2 control agonist affinity on
GB1. (a) Schemes depict a dimeric GABAB receptor according to our actual view of the
“resting” (Left) and “active” state (Right). GB1 and GB2 subunits are in dark gray and white,
respectively. In their “resting” orientation, both VFT modules in the dimer are in the open
state, as observed in the crystal structure of the empty form of metabotropic receptor mGlu1
(PDB ID code 1ewt). One VFT is in the front plane (dark gray), whereas the other is in the
back plane (white). The axis for the rotation of one VFT relative to the other and is indicated
with a black circle, and the axis in each VFT responsible for their closure is indicated with an
open circle. GABA (black box) binds in the cleft that separates both lobes of GB1 VFT and
induces its closure leading to the active state. Each HD of GB1 and GB2 is composed of
seven transmembrane helices (oval boxes) connected by extra- and intra-cellular loops, and C-
terminus regions of the two subunits are associated (dark gray lines). Asterisk shows lobe-II
of GB1 which is believed to interact with HD of GB1 and be responsible of the inhibitory
contact inside GB1. (b) Displacement curves of [125I]CGP64213 with GABA on cells
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expressing GB1ASA (❍), GB1 + GB2 () and GB1 + GB2/1 (❑), where GB2/1 is a chimeric
subunit composed of the VFT of GB2 and the HD of GB1. Percentage of bound radioligand
for each concentration of GABA is plotted. Inhibitory concentration of GABA corresponding
to the displacement of fifty percent of the initial bound radioligand (IC50) is plotted for the
three receptors. Values are means ± s.e.m. of at least three experiments performed in
triplicates.
Figure 2: VFT module constructs for GB1 and GB2 (a) Schemes of each individual
constructs. VFT of GB1 (dark gray) and GB2 (white) were expressed with TM1 segment of
the HD domain of GB1 (dark gray oval) and GB2 (white oval), respectively, or with a GPI
anchor sequence (broken lines). VFT of mGlu5 (black) called ∆mG5 and a VFT of GB1
harboring a mutation S246A were expressed using TM1 segment of their own receptor. (b)
Western blot analysis of the GB1 and GB2 constructs. The arrows indicate bands
corresponding to ∆GB1 (lane 1), ∆GB2 (lanes 2), GB1GPI (lane 4) and GB2GPI (lane 5) and
they are absent in mock-transfected cells (lanes 3 and 6). Constructs have an apparent
molecular weight close to 60 kDa, as expected. (c) Cell surface expression of each individual
HA-tagged constructs was measured by ELISA. Values are means ± s.e.m. of triplicates from
a typical experiment and they are shown in arbitrary unit (A.U.). Although total expression of
GB2GPI is similar to that of GB1GPI, GB2GPI failed to reach the cell surface. (d) In white,
binding of [125I]CGP64213 for ∆GB1 and GB1GPI constructs expressed as a percentage of
GB1ASA. Specific binding is shown by the radioligand displacement by 1 mM GABA (black
bars). Data are means ± s.e.m. of at least three experiments performed in triplicates.
32
Figure 3: Cell surface expression of ∆GB1 and GB1GPI is increased by ∆GB2 and GB2.
(a) Binding of radioligand on ∆GB1 and GB1GPI expressed alone or in combination with
∆GB2 or GB2. Data are means ± s.e.m. of at least three experiments performed in triplicates,
and are expressed as percentage of the specific binding measured in cells expressing GB1ASA.
(b) Amount at the cell surface of ∆GB1 expressed alone or in combination with ∆GB2, GB2
or GB1ASA as measured by ELISA. Values are means ± s.e.m. of triplicates from a typical
experiment and they are shown in arbitrary unit (A.U.)
Figure 4: Association between VFT modules of ∆GB1 and ∆GB2 in time-resolved FRET
experiments. (a) Amount of FRET signal between co-expressed HA-tagged ∆GB1 and c-
myc-tagged constructs. FRET signals are shown as ∆F (See Materials and Methods). In insert,
scheme depicts the experimental system where VFT modules of GB1 (dark gray) and GB2
(white) are bound to a donor molecule (europium cryptate-PBP) linked to an anti-HA
monoclonal antibody and to an acceptor molecule (Alexa Fluor® 647) linked to an anti-c-myc
monoclonal antibody, respectively. FRET signal between the two antibodies is measured at
665 nm (E665) after excitation at 337 nm. (b) Amount of c-myc tagged constructs as
measured by the fluorescence of Alexa Fluor® 647 antibody at 682 nm (E682). Signal
intensities are normalized relative to GB2. Values are means ± s.e.m. of triplicates from a
typical experiment. (c) ∆F FRET signal was normalized by the amount of c-myc-tagged
constructs expressed at the cell surface. Experiments were done at least three times.
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Figure 5: GB1GPI and ∆GB2 interact together specifically in time-resolved FRET
experiments. (a) Amount of FRET signal ∆F between co-expressed HA-tagged GB1GPI and c-
myc-tagged constructs, similarly to Figure 4. (b) Amount of c-myc tagged constructs as
measured by the fluorescence emission of Alexa Fluor® 647 antibody (E682). Signal
intensities are normalized relative to GB2. (c) ∆F FRET signal was normalized by the amount
of c-myc-tagged constructs expressed at the cell surface. Experiments were done at least three
times.
Figure 6: Association between VFT modules of GB1 and GB2 increases agonist affinity
on GB1. (a) Displacement curves of [125I]CGP64213 with GABA on cells expressing GB1ASA
alone (❍) or in combination with ∆GB2 ( ), ∆mG5 () or ∆ GB1(S246A) (❑), as a
percentage of bound radioligand (upper panel). IC50 were plotted from the displacement curve
(lower panel). Values are means ± s.e.m. of at least three experiments performed in triplicates.
In upper panel insert, association between HA-tagged GB1ASA and c-myc-tagged ∆GB2,
∆mG5 or ∆GB1(S246A) constructs as measured in time-resolved FRET experiments. (b)
Displacement curves of the radioligand with GABA on cells expressing ∆GB1 alone () or in
combination with ∆GB2 () or GB2 (❑), and corresponding GABA IC50.
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